Papers by Alessandra Macciotta
Padroni L, 2023
The analysis of circulating tumor cells and tumor-derived materials, such as circulating
tumor DN... more The analysis of circulating tumor cells and tumor-derived materials, such as circulating
tumor DNA, circulating miRNAs (cfmiRNAs), and extracellular vehicles provides crucial information
in cancer research. CfmiRNAs, a group of short noncoding regulatory RNAs, have gained attention
as diagnostic and prognostic biomarkers. This review focuses on the discovery phases of cfmiRNA
studies in breast cancer patients, aiming to identify altered cfmiRNA levels compared to healthy
controls. A systematic literature search was conducted, resulting in 16 eligible publications. The
studies included a total of 585 breast cancer cases and 496 healthy controls, with diverse sample types
and different cfmiRNA assay panels. Several cfmiRNAs, including MIR16, MIR191, MIR484, MIR106a,
and MIR193b, showed differential expressions between breast cancer cases and healthy controls.
However, the studies had a high risk of bias and lacked standardized protocols. The findings highlight
the need for robust study designs, standardized procedures, and larger sample sizes in discovery
phase studies. Furthermore, the identified cfmiRNAs can serve as potential candidates for further
validation studies in different populations. Improving the design and implementation of cfmiRNA
research in liquid biopsies may enhance their clinical diagnostic utility in breast cancer patients.
Uploads
Papers by Alessandra Macciotta
tumor DNA, circulating miRNAs (cfmiRNAs), and extracellular vehicles provides crucial information
in cancer research. CfmiRNAs, a group of short noncoding regulatory RNAs, have gained attention
as diagnostic and prognostic biomarkers. This review focuses on the discovery phases of cfmiRNA
studies in breast cancer patients, aiming to identify altered cfmiRNA levels compared to healthy
controls. A systematic literature search was conducted, resulting in 16 eligible publications. The
studies included a total of 585 breast cancer cases and 496 healthy controls, with diverse sample types
and different cfmiRNA assay panels. Several cfmiRNAs, including MIR16, MIR191, MIR484, MIR106a,
and MIR193b, showed differential expressions between breast cancer cases and healthy controls.
However, the studies had a high risk of bias and lacked standardized protocols. The findings highlight
the need for robust study designs, standardized procedures, and larger sample sizes in discovery
phase studies. Furthermore, the identified cfmiRNAs can serve as potential candidates for further
validation studies in different populations. Improving the design and implementation of cfmiRNA
research in liquid biopsies may enhance their clinical diagnostic utility in breast cancer patients.